Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Working Capital to Net Assets Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Working Capital to Net Assets ratio of 66.5% as of September 2025. Working capital of CN¥775.33 Million (current assets of CN¥1.75 Billion minus current liabilities of CN¥974.78 Million) is measured against net assets of CN¥1.17 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 688621 net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Beijing Sun Novo Pharmaceutical Research Co Ltd Working Capital to Net Assets (2017–2024)
This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Working Capital to Net Assets ratio has evolved across 8 annual periods from 2017 to 2024. As of September 2025, the ratio stands at 66.5%, reflecting working capital of CN¥775.33 Million against net assets of CN¥1.17 Billion CNY. Check 688621 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2024, covering 8 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Beijing Sun Novo Pharmaceutical Research stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 66.7% | CN¥735.93 Million | CN¥1.10 Billion | CN¥1.51 Billion | CN¥778.56 Million | ▲ +10.4 pp |
| 2023 | 56.4% | CN¥595.93 Million | CN¥1.06 Billion | CN¥1.36 Billion | CN¥761.21 Million | ▼ -1.1 pp |
| 2022 | 57.4% | CN¥521.77 Million | CN¥908.23 Million | CN¥1.04 Billion | CN¥518.19 Million | ▼ -10.6 pp |
| 2021 | 68.1% | CN¥523.96 Million | CN¥769.64 Million | CN¥941.79 Million | CN¥417.83 Million | ▲ +31.3 pp |
| 2020 | 36.8% | CN¥70.94 Million | CN¥192.92 Million | CN¥262.87 Million | CN¥191.94 Million | ▲ +24.3 pp |
| 2019 | 12.4% | CN¥14.77 Million | CN¥118.76 Million | CN¥181.53 Million | CN¥166.76 Million | ▲ +18.9 pp |
| 2018 | -6.4% | CN¥-4.74 Million | CN¥73.82 Million | CN¥119.07 Million | CN¥123.81 Million | ▲ +0.5 pp |
| 2017 | -6.9% | CN¥-2.31 Million | CN¥33.25 Million | CN¥65.78 Million | CN¥68.08 Million | — |